After a rocky two years, money has started flowing back to biotech, with the return of the megaround exemplified in top moneymaker Xaira’s $1 billion fundraise.

The company is handing back the tumor candidate it snapped up in 2021 after initiating a phase 2 trial of the anti-ITL2 monoclonal antibody.

Frazier Life Sciences has launched Callio Therapeutics with $187 million in series A funds and a HER2-targeted dual-payload antibody-drug conjugate that’s ready for the clinic.

With Sunday’s Academy Awards ceremony in the rearview mirror, GSK is looking ahead to a potential blockbuster debut of its own. The British Big Pharma has filed depemokimab for FDA approval in two respiratory indications on the back of new phase 3 data showing the antibody improved disease symptoms and quality of life in patients with chronic rhinosinusitis with nasal polyps.

Lexicon Pharmaceuticals is yet again defending a mixed set of data on its non-opioid pain prospect. The biotech focused on low-dose results from its latest phase 2 trial, rather than the overall primary endpoint miss, but investors took a much more downbeat view of the data.

Novo Nordisk has forged a deal with Gensaic, agreeing to pay up to $354 million per target to access technology for the tissue-selective delivery of molecules to cardiometabolic targets inside cells.

A new policy from President Donald Trump aims to restrict both inbound and outbound investments related to China in certain strategic industries, including biotechnology.

Public health experts are sounding the alarm about the outbreak and warn that communities with low immunization rates are at greatest risk for further spread of the disease.

Once again, Eli Lilly is using Hollywood’s biggest night as a platform to speak out on a hot-button issue in pharma.